---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-035372"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2022-12-14T23:59:59+00:00"
generated_at: "2026-06-21T04:38:20.959818+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harrow buys exclusive U.S. rights to five Novartis ophthalmic drugs for $130M upfront

## Summary
- Deal: $130M upfront plus up to $45M milestone on TRIESENCE commercial availability; Q1 2023 close subject to HSR clearance.
- Products: ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, TRIESENCE – FDA-approved for cataract surgery, infection, inflammation, and vitrectomy.
- During ~6-month NDA transfer, Novartis continues sales and remits net profit to Harrow; thereafter Harrow controls U.S. market.
- 2023 guidance: net revenue $135-143M, adjusted EBITDA $44-50M, with both expected to ramp in 2024+.
- CEO calls it a landmark transaction that positions Harrow as a leader in the U.S. ophthalmic pharmaceuticals market.

## SEC filing metadata
- accession: 0001493152-22-035372
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2022-12-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315222035372/0001493152-22-035372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315222035372/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-035372
- JSON: https://secwatch.observer/filing/0001493152-22-035372.json
- Plain text: https://secwatch.observer/filing/0001493152-22-035372.txt

## Key facts
- Material Agreements
  HARROW, INC. entered into Asset Purchase Agreement with Novartis Technology, LLC and Novartis Innovative Therapies AG valued at $130,000,000 (effective 2022-12-13).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Novartis Technology, LLC and Novartis Innovative Therapies AG
  - Value: $130,000,000
  - Effective: 2022-12-13
  source text: On December 13, 2022, Harrow Health, Inc. along with its wholly-owned subsidiaries, Harrow IP, LLC and Harrow Eye, LLC (individually and together the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Novartis Technology, LLC and Novartis Innovative Therapies AG (together, “Novartis”), pursuant to which the Company agreed to purchase from Novartis the exclusive commercial rights to assets associated with the following ophthalmic products (collectively the “Products”) in the U.S. (the “Acquisition”): ILEVRO® (nepafenac ophthalmic suspension) 0.3%; NEVANAC® (nepafenac ophthalmic suspension) 0.1%; VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5%; MAXIDEX® (dexamethasone ophthalmic suspension) 0.1%; and TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/ml.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315222035372/0001493152-22-035372-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.